Rationally designed peptides relieve ischemic stroke by targeting TRPM2 intramolecular interactions.
Rational peptide design is making waves again. This time, a team out of Zhejiang University has built a peptide inhibitor—M2IP—that targets TRPM2, a cation channel heavily involved in ischemic stroke. Most small-molecule inhibitors fumble with TRPM2 because they hit conserved sites, so they’re blunt tools. M2IP is different. The researchers locked in on a unique inter-subunit interface (interface III), designing a peptide that zeroes in on that spot and nothing else.
Pharmacol Res
by Yao J, You Q, Liu X et al.
“Rationally designed peptides relieve ischemic stroke by targeting TRPM2 intramolecular interactions. Yao J(1), You Q(2), Liu X(1), Zhen W(1), Fang M(1), Luo Y(1), Wu J(3), Mai Z(1), Yu P(1), Yang F(4), Yang W(5). Author information: (1)Department of Biophysics, Department of Neurobiology of the Forth Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. (2)Department of Biophysics, Department of Neurobiology of the Forth Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Department of Pharmacology, School of Pharmacy, Ningxia Medical University, Yinchuan, 750004, China. (3)School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, China. (4)Department of Biophysics, Department of Neurobiology of the Forth Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: fanyanga@zju.edu.cn. (5)Department of Biophysics, Department of Neurobiology of the Forth Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Guizhou University School of Medicine, Guiyang, 550025, China; School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, China. Electronic address: yangwei@zju.edu.cn. TRPM2 is a calcium-permeable cation channel that functions as an oxidative stress sensor and plays a key role in various pathologies, particularly ischemic stroke. The activation of hsTRPM2 requires cooperative engagement of its N‑ and C‑terminal domains, a mechanism distinct among TRP channels. Existing small-molecule inhibitors, which primarily target conserved pore and ligand-binding regions, often suffer from limited specificity and poor efficacy, hampering their clinical translation. Therefore, we designed a TRPM2 peptide inhibitor (M2IP) by targeting the unique inter‑subunit interface (interface III) within TRPM2. M2IP exhibited sub‑micromolar inhibitory potency and high selectivity over other TRP channels. Electrophysiology and calcium imaging showed that it effectively suppressed TRPM2-mediated currents and calcium influx. In the mouse model of ischemic stroke, M2IP treatment significantly alleviated brain injury. This study not only develops M2IP as a potent and specific TRPM2 inhibitor, also sheds new light on developing peptide therapeutics against ion channels. Copyright © 2026. Published by Elsevier Ltd. Conflict of interest statement: Declaration of Competing Interest All authors declare the absence of any conflict of interest.”
Here’s what matters:
TRPM2 isn’t just any ion channel. It acts as an oxidative stress sensor, and its N- and C-terminal domains have to cooperate for activation. That’s not how most TRP channels work.
M2IP inhibits TRPM2 with sub-micromolar potency. That’s tight binding, especially for a peptide.
Selectivity is high. M2IP doesn’t mess with other TRP channels, dodging the off-target mess that plagues small molecules.
In mouse models of ischemic stroke, M2IP actually reduced brain injury. Less damage, more hope for targeted interventions.
Key takeaway: Rationally designed peptides like M2IP aren’t just “blocking” ion channels—they’re surgically precise. The approach opens up new routes for researchers who want selectivity and efficacy, especially in complex neurological models.
This isn’t just about one peptide. The strategy could apply to a whole range of ion channels where small molecules fall short. Anyone tracking the future of peptide research should pay attention. Want to dig deeper into methods or see where to source similar research compounds? Check the vendor directory.
Ion channel modulation just got a serious upgrade, and peptide research is leading the charge.
Related Reading
Eu(3+)-mediated dual-crosslinked collagen-mimetic peptide/sodium alginate hydrogel for 3D-printed skin wound dressings.
News · Acta BiomaterAntimicrobial-potentiated colorectal cancer therapy with synchronized tumoricidal immunity via a self-deliverable nanopeptide.
News · J Am Pharm Assoc (2003)Real-world weight impact upon tirzepatide discontinuation at a single-center endocrinology clinic in patients with overweight or obesity.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.